Format

Send to

Choose Destination
Neurobiol Aging. 2009 Mar;30(3):501-2. Epub 2007 Aug 27.

Case control analysis of LRRK2 Gly2385Arg in Alzheimer's disease.

Author information

1
Department of Neurology, Singapore General Hospital, Singapore. gnrtek@sgh.com.sg

Abstract

Alzheimer's disease (AD) pathology has been described in Parkinson's disease (PD) patients with leucine-rich repeat kinase-2 (LRRK2) mutations. A common LRRK2 Gly2385Arg variant has been widely shown to be associated with a twofold increased risk of PD in various Asian populations. In a case control study, the frequency of the heterozygous Gly2385Arg genotype was demonstrated in 4.3% of AD compared to 4.5% in controls (odds ratio=0.94, 95% CI 0.37-2.42, p=1.0). The Gly2385Arg variant does not appear to modulate the risk of AD in our population.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center